Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Eyes Longer-Lasting Stomach Acid Drug (Japan)

This article was originally published in PharmAsia News

Executive Summary

Eisai Co. is working on a follow-up to Pariet, its drug for stomach ulcers, acid reflux, and related gastrointestinal problems. U.S. patents on Pariet, which is sold in America as Aciphex, expire in May 2013. Eisai hopes to have the new product ready by May 2013, when U.S. patents on the drug, which is marketed in the United States as Aciphex, expire. Eisai says the new drug will be longer-lasting and more effective than Pariet at blocking secretion of stomach acid at night. The third and final phase of clinical testing will begin as early as 2008 in the U.S. The company plans to apply for marketing approval in fiscal 2009. (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel